文献速递姑息放疗与转移瘤放疗物理与技术

长骨转移瘤的立体定向体部放射治疗

Stereotactic Body Radiation Therapy for Metastases in Long Bones.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-07-16

回顾性分析7个国际中心2011年10月至2021年2月收治的111例患者共114处长骨(股骨、肱骨、胫骨)转移瘤接受立体定向体部放射治疗(SBRT)的数据,采用竞争风险回归模型分析骨折和局部失败累积发生率及相关危险因素。中位随访21个月,1、2、3年骨折累积发生率分别为3.5%、6.1%、9.8%,局部失败累积发生率分别为5.7%、7.2%、13.5%;多因素分析显示骨外疾病延伸与骨折(P=0.001;亚风险比10.8;95%CI 2.8-41.9)和局部失败(P=0.02;亚风险比7.9;95%CI 1.4-44.7)显著相关。作者认为长骨转移瘤SBRT实现了较高的持久局部转移控制率,且未增加骨折风险;与脊柱SBRT类似,骨外疾病延伸患者局部失败和骨折风险更高。

要点

  • 长骨转移瘤SBRT后1、2、3年骨折累积发生率分别为3.5%、6.1%、9.8%。
  • 局部失败累积发生率1年5.7%、2年7.2%、3年13.5%。
  • 骨外疾病延伸与骨折(P=0.001;亚风险比10.8;95%CI 2.8-41.9)和局部失败(P=0.02;亚风险比7.9;95%CI 1.4-44.7)显著相关。

核心结论

  • 长骨转移瘤SBRT实现了较高的持久局部转移控制率,且未增加骨折风险。
  • 与脊柱SBRT类似,骨外疾病延伸患者局部失败和骨折风险更高。

研究设计与样本

  • 回顾性分析7个国际中心2011年10月至2021年2月收治的111例患者共114处股骨、肱骨和胫骨转移瘤接受SBRT的数据,采用竞争风险回归模型分析。

主要发现

  • 中位随访21个月(范围6-91个月)。
  • 除1例患者外,其余患者卡氏功能状态评分≥70。
  • 转移瘤部位:股骨84处(73.7%)、肱骨26处(22.8%)、胫骨4处(3.5%)。
  • 原发肿瘤:前列腺癌45处(39.5%)、乳腺癌22处(19.3%)、肺癌15处(13.2%)、肾癌13处(11.4%)、其他19处(16.6%)。
  • 寡转移占74.8%,溶骨性转移占28.1%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the cumulative incidence of fracture and local failure and associated risk factors after stereotactic body radiation therapy (SBRT) for long bone metastases. METHODS AND MATERIALS: Data from 111 patients with 114 metastases in the femur, humerus, and tibia treated with SBRT in 7 international centers between October 2011 and February 2021 were retrospectively reviewed and analyzed using a competing risk regression model. RESULTS: The median follow-up was 21 months (range, 6-91 months). All but 1 patient had a Karnofsky performance status ≥70. There were 84 femur (73.7%), 26 humerus (22.8%), and 4 tibia (3.5%) metastases from prostate (45 [39.5%]), breast (22 [19.3%]), lung (15 [13.2%]), kidney (13 [11.4%]), and other (19 [16.6%]) malignancies. Oligometastases accounted for 74.8% of metastases and 28.1% were osteolytic. The most common total doses were 30 to 50 Gy in 5 daily fractions (50.9%). Eight fractures (5 in the femur, 2 in the tibia, and 1 in the humerus) were observed with a median time to fracture of 12 months (range, 0.8-33 months). In 6 out of 8 patients, fracture was not associated with local failure. The cumulative incidence of fracture was 3.5%, 6.1%, and 9.8% at 1, 2, and 3 years, respectively. The cumulative incidence of local failure (9/110 metastases with imaging follow-up) was 5.7%, 7.2%, and 13.5% at 1, 2, and 3 years, respectively. On multivariate analysis, extraosseous disease extension was significantly associated with fracture (P = .001; subhazard ratio, 10.8; 95% confidence interval, 2.8-41.9) and local failure (P = .02; subhazard ratio, 7.9; 95% confidence interval, 1.4-44.7). CONCLUSIONS: SBRT for metastases in long bones achieved high rates of durable local metastasis control without an increased risk of fracture. Similar to spine SBRT, patients with extraosseous disease extension are at higher risk of local failure and fracture.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Madani I, Sahgal A, Erler D, et al. Stereotactic Body Radiation Therapy for Metastases in Long Bones. Int J Radiat Oncol Biol Phys. 2022. PMID: 35850362. doi:10.1016/j.ijrobp.2022.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。